Ural Ülkü Mete
Department of Obstetrics and Gynecology, Faculty of Medicine, Bolu Abant İzzet Baysal University, Gölköy Yerleşkesi, 14030, Bolu, Turkey.
Arch Gynecol Obstet. 2024 May;309(5):2229-2236. doi: 10.1007/s00404-024-07431-3. Epub 2024 Feb 29.
The complications of surgical treatments of stress urinary incontinence have led to the search for less invasive and safer treatment procedures. We aimed to investigate the efficacy of locally administered injectable platelet-rich fibrin (i-PRF), an autologous material that plays an important role in tissue regeneration, in women with stress urinary incontinence.
Thirty-four women were included in this prospective, single-center, and interventional study, suffering from stress urinary incontinence refractory to conservative treatment. Three consecutive i-PRF injections were applied to the mid-urethra localization at anterior vaginal wall with an interval of 1 month. ICIQ-SF, UDI-6, IIQ-7 and POPDI-6 questionnaires were used to measure pre‑treatment, 1 month and 6 months post‑treatment symptom severity and the clinical outcomes were recorded.
The mean age of the patients was 51.5 ± 9.8 years. ICIQ-SF, UDI-6, IIQ-7 and POPDI-6 questionnaires results revealed significant clinical improvement of stress urinary incontinence severity afer the administration of i-PRF (p < 0.001). The results at 1 and 6 months after treatment did not change statistically significantly.
This study demonstrated that locally administiration of i-PRF is efective in relieving SUI symptoms with high success rates without any adverse effects reported. i-PRF injection may have the potential to be a novel, minimally invasive, and low-risk procedure, that could be an alternative and simple treatment modality to surgery for female patients with stress urinary incontinence. Additionally, it may create new avenues for research on therapeutic implementation of i-PRF.
压力性尿失禁手术治疗的并发症促使人们寻找侵入性更小、更安全的治疗方法。我们旨在研究局部注射富血小板纤维蛋白（i-PRF）（一种在组织再生中起重要作用的自体材料）对压力性尿失禁女性患者的疗效。
34名患有保守治疗无效的压力性尿失禁的女性被纳入这项前瞻性、单中心干预性研究。在阴道前壁尿道中段连续进行3次i-PRF注射，间隔1个月。使用ICIQ-SF、UDI-6、IIQ-7和POPDI-6问卷来测量治疗前、治疗后1个月和6个月的症状严重程度，并记录临床结果。
患者的平均年龄为51.5±9.8岁。ICIQ-SF、UDI-6、IIQ-7和POPDI-6问卷结果显示，注射i-PRF后压力性尿失禁严重程度有显著临床改善（p<0.001）。治疗后1个月和6个月的结果在统计学上没有显著变化。
本研究表明，局部注射i-PRF可有效缓解压力性尿失禁症状，成功率高，且未报告任何不良反应。i-PRF注射可能有潜力成为一种新颖、微创且低风险的手术，对于压力性尿失禁女性患者而言，可以作为手术的一种替代且简单的治疗方式。此外，它可能为i-PRF治疗应用的研究开辟新途径。
